ARWR compared with KRYS: revenue, margins and what each company keeps, and the suppliers and customers both name

ARWRArrowhead Pharmaceuticals, Inc.

Mkt capRevenueRevenue

KRYSKrystal Biotech, Inc.

Mkt capRevenueRevenue

Compare

ARWRArrowhead Pharmaceuticals, Inc.

KRYSKrystal Biotech, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ARWR

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±8.5%▼−2.99%×0.35

Q2 FY26±7.3%▼−6.75%×0.93

Q1 FY26±11.4%▼−0.19%×0.02

Nov 26 '25±13.6%▲+23.34%×1.71

KRYS

2 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±8.7%▼−10.95%×1.25

Q2 FY26±10.1%▼−8.37%×0.83

= impliedARWR realized, solidKRYS realized, hatchedOne scale, both sides: full bar = 24%× = |realized| ÷ impliedSource: market data

Q1 FY26

±8.1%

▲+4.12%

×0.51

Jan 12 '26±3.8%▲+4.10%×1.08

ARWRArrowhead Pharmaceuticals, Inc.

60.68· pre 59.68· delayed

Mkt cap$8.5BRevenue$75MQ3 FY26Revenue$829MFY25

KRYSKrystal Biotech, Inc.

295.30· pre 295.27· delayed

Pre-marketNov 2 '26delayed

Mkt cap$8.8BRevenue$127MQ3 FY26Revenue$389MFY25

Compare

Pre-marketNov 2 '26delayed

ARWRArrowhead Pharmaceuticals, Inc.

KRYSKrystal Biotech, Inc.

60.68pre 59.68delayed

Price

295.30pre 295.27delayed

$8.5B

Mkt cap

$8.8B

Q3 FY26$75M

Revenue

$127MQ3 FY26

FY25$829M

Revenue

$389MFY25

ARWR60.68vsKRYS295.30Pre-marketNov 2 '26delayed